Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. ...
Barchart Research What to Expect from AUPH Earnings AUPH Generated August 5, 2026 Current Price $15.19 EPS Estimate $$0.18 Consensus Rating Moderate Buy Average Move 5.32% Aurinia's Guidance Called for...
Barchart Research What to Expect from AUPH Earnings AUPH Generated July 29, 2026 Current Price $15.18 EPS Estimate $$0.18 Consensus Rating Moderate Buy Average Move 5.32% AUPH Reports Tomorrow With Analysts...
— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need —
— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress —
Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer for...
Barchart Research What to Expect from AUPH Earnings AUPH Generated May 8, 2026 Current Price $15.23 EPS Estimate $$0.19 Consensus Rating Moderate Buy Average Move 4.54% Aurinia Reports Another Quarter...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial...